Drug intelligence / Profile preview

GM2813

Development stage: Preclinical
Lead developer: Grey Matter Pharma
Modality: Small Molecules

Overview

GM2813 is an investigational drug candidate being developed by Grey Matter Pharma for the treatment of gambling disorder. It is part of a pipeline focused on central nervous system (CNS) disorders and behavioral addictions. While the specific mechanism of action and chemical identity have not been fully disclosed, Grey Matter Pharma specializes in utilizing proprietary delivery technologies, such as fast-dissolve sublingual platforms, to optimize the pharmacokinetic profiles of established compounds for addiction medicine. GM2813 is currently in the early stages of development within the company's research pipeline.

Beyond the preview

Go deeper on GM2813.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GM2813.

Explore the full profile